254 related articles for article (PubMed ID: 23415892)
1. ADAM17, shedding, TACE as therapeutic targets.
Rose-John S
Pharmacol Res; 2013 May; 71():19-22. PubMed ID: 23415892
[TBL] [Abstract][Full Text] [Related]
2. ADAM17: a molecular switch to control inflammation and tissue regeneration.
Scheller J; Chalaris A; Garbers C; Rose-John S
Trends Immunol; 2011 Aug; 32(8):380-7. PubMed ID: 21752713
[TBL] [Abstract][Full Text] [Related]
3. Short-term TNFα shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17.
Schwarz J; Broder C; Helmstetter A; Schmidt S; Yan I; Müller M; Schmidt-Arras D; Becker-Pauly C; Koch-Nolte F; Mittrücker HW; Rabe B; Rose-John S; Chalaris A
Biochim Biophys Acta; 2013 Dec; 1833(12):3355-3367. PubMed ID: 24135057
[TBL] [Abstract][Full Text] [Related]
4. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1.
Canault M; Leroyer AS; Peiretti F; Lesèche G; Tedgui A; Bonardo B; Alessi MC; Boulanger CM; Nalbone G
Am J Pathol; 2007 Nov; 171(5):1713-23. PubMed ID: 17872973
[TBL] [Abstract][Full Text] [Related]
5. ADAM17 as a therapeutic target in multiple diseases.
Arribas J; Esselens C
Curr Pharm Des; 2009; 15(20):2319-35. PubMed ID: 19601834
[TBL] [Abstract][Full Text] [Related]
6. The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress.
Rzymski T; Petry A; Kračun D; Rieß F; Pike L; Harris AL; Görlach A
Oncogene; 2012 Aug; 31(31):3621-34. PubMed ID: 22105359
[TBL] [Abstract][Full Text] [Related]
7. ADAM17 at the interface between inflammation and autoimmunity.
Lisi S; D'Amore M; Sisto M
Immunol Lett; 2014 Nov; 162(1 Pt A):159-69. PubMed ID: 25171914
[TBL] [Abstract][Full Text] [Related]
8. TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption.
Fréour T; Jarry A; Bach-Ngohou K; Dejoie T; Bou-Hanna C; Denis MG; Mosnier JF; Laboisse CL; Masson D
Int J Mol Med; 2009 Jan; 23(1):41-8. PubMed ID: 19082505
[TBL] [Abstract][Full Text] [Related]
9. [The two sides of ADAM17 in inflammation: implications in atherosclerosis and obesity].
Peiretti F; Canault M; Morange P; Alessi MC; Nalbone G
Med Sci (Paris); 2009 Jan; 25(1):45-50. PubMed ID: 19154693
[TBL] [Abstract][Full Text] [Related]
10. The TNFα converting enzyme (TACE) from ayu (Plecoglossus altivelis) exhibits TNFα shedding activity.
Lu XJ; Chen Q; Yang GJ; Chen J
Mol Immunol; 2015 Feb; 63(2):497-504. PubMed ID: 25458310
[TBL] [Abstract][Full Text] [Related]
11. TACE: a new target in epidermal growth factor receptor dependent tumors.
Kenny PA
Differentiation; 2007 Nov; 75(9):800-8. PubMed ID: 17608729
[TBL] [Abstract][Full Text] [Related]
12. TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis.
Becker-Pauly C; Rose-John S
EMBO Mol Med; 2013 Jul; 5(7):970-2. PubMed ID: 23757215
[No Abstract] [Full Text] [Related]
13. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice.
Chalaris A; Adam N; Sina C; Rosenstiel P; Lehmann-Koch J; Schirmacher P; Hartmann D; Cichy J; Gavrilova O; Schreiber S; Jostock T; Matthews V; Häsler R; Becker C; Neurath MF; Reiss K; Saftig P; Scheller J; Rose-John S
J Exp Med; 2010 Aug; 207(8):1617-24. PubMed ID: 20603312
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive effect of a novel, selective TACE inhibitor on DMBA- and TPA-induced skin carcinogenesis.
Sharma M; Mohapatra J; Argade A; Deshpande SS; Shah GB; Chatterjee A; Jain MR
Immunopharmacol Immunotoxicol; 2014 Aug; 36(4):282-9. PubMed ID: 24946851
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen sulfide reduces cell adhesion and relevant inflammatory triggering by preventing ADAM17-dependent TNF-α activation.
Perna AF; Sepe I; Lanza D; Capasso R; Zappavigna S; Capasso G; Caraglia M; Ingrosso D
J Cell Biochem; 2013 Jul; 114(7):1536-48. PubMed ID: 23297114
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the cDNA and gene for mouse tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and its location to mouse chromosome 12 and human chromosome 2p25.
Cerretti DP; Poindexter K; Castner BJ; Means G; Copeland NG; Gilbert DJ; Jenkins NA; Black RA; Nelson N
Cytokine; 1999 Aug; 11(8):541-51. PubMed ID: 10433800
[TBL] [Abstract][Full Text] [Related]
17. A brief history of tumor necrosis factor α--converting enzyme: an overview of ectodomain shedding.
Horiuchi K
Keio J Med; 2013; 62(1):29-36. PubMed ID: 23563789
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling for the identification of small-molecule inhibitors of TACE.
Liu LJ; Leung KH; Lin S; Chan DS; Susanti D; Rao W; Chan PW; Ma DL; Leung CH
Methods; 2015 Jan; 71():92-7. PubMed ID: 25260600
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.
Moss ML; Minond D
Mediators Inflamm; 2017; 2017():9673537. PubMed ID: 29230082
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C (PKC) increases TACE/ADAM17 enzyme activity in porcine ovarian somatic cells, which is essential for granulosa cell luteinization and oocyte maturation.
Yamashita Y; Okamoto M; Ikeda M; Okamoto A; Sakai M; Gunji Y; Nishimura R; Hishinuma M; Shimada M
Endocrinology; 2014 Mar; 155(3):1080-90. PubMed ID: 24424050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
